Innate Pharma S.A. (FRA:IDD)
1.660
+0.002 (0.12%)
At close: Nov 28, 2025
Innate Pharma Employees
Innate Pharma had 181 employees as of December 31, 2024. The number of employees increased by 2 or 1.12% compared to the previous year.
Employees
181
Change (1Y)
2
Growth (1Y)
1.12%
Revenue / Employee
€72,621
Profits / Employee
€264,661
Market Cap
159.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 181 | 2 | 1.12% |
| Dec 31, 2023 | 179 | -32 | -15.17% |
| Dec 31, 2022 | 211 | -4 | -1.86% |
| Dec 31, 2021 | 215 | -29 | -11.89% |
| Dec 31, 2020 | 244 | 9 | 3.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 318,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 103,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Innate Pharma News
- 3 days ago - Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 - Business Wire
- 14 days ago - Innate Pharma to Present at Jefferies Global Healthcare Conference - Business Wire
- 18 days ago - Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Innate Pharma (IPHA) Reports Significant Revenue Decline in 9M 2025 - GuruFocus
- 18 days ago - Innate Pharma reports 9M results - Seeking Alpha
- 18 days ago - Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Business Wire
- 21 days ago - Innate Pharma (IPHA) Gains FDA Approval to Advance Phase 3 Lacutamab Trial - GuruFocus
- 21 days ago - Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL - Wallstreet:Online